

Ascent Industries Reports First Quarter 2024 Results

OAK BROOK, III.--(BUSINESS WIRE)-- Ascent Industries Co. (Nasdaq: ACNT) ("Ascent" or the "Company"), an industrials company focused on the production of specialty chemicals and industrial tubular products, is reporting its results for the first quarter ended March 31, 2024.

First Quarter 2024 Summary¹

(in millions, except per share and margin)	Q1 2024	Q1 2023	Change
Net Sales	\$44.1	\$54.9	(19.6)%
Gross Profit	\$2.5	\$1.5	72.4%
Gross Profit Margin	5.7%	2.7%	300bps
Net (Loss)	\$(4.7)	\$(5.8)	18.6%
Diluted (Loss) per Share	\$(0.47)	\$(0.57)	17.5%
Adjusted EBITDA	\$(3.1)	\$(3.7)	16.6%
Adjusted EBITDA Margin	(7.1)%	(6.8)%	(30)bps

¹ On June 2, 2023, the Board of Directors of Ascent made the decision to permanently cease operations at the Company's welded pipe and tube facility located in Munhall, PA ("Munhall") effective on August 31, 2023. On December 22, 2023, the Company closed on a transaction to sell substantially all of the assets of Specialty Pipe & Tube ("SPT"). As a result, financial results from Munhall & SPT have been categorized into discontinued operations.

Management Commentary

"The first quarter of 2024 marked a period of structural cost reduction and stabilization efforts across the enterprise," said Ascent CEO Bryan Kitchen. "Without question, our initial efforts to optimize both cash and costs have helped drive year-over-year improvements across our consolidated gross margin and bottom line, while operating within the confines of our own free cash flow. Aggressive self-help has been at the core of our ability to overcome ongoing market headwinds that have resulted in a year-over-year decline in total net sales.

"As promised, in just a short period of time we have made progress in laying the groundwork for driving profitable growth through the optimization of our product mix while recapitalizing our SG&A across both segments. These actions, coupled with a continued focus on driving efficiencies across all sites and functions, will create a more predictable, reliable, and profitable operating model moving forward. Momentum is building, and we expect continued improvements in our financial results throughout 2024. We believe we are on the right track to create durable value for shareholders."

First Quarter 2024 Financial Results

Net sales from continuing operations were \$44.1 million compared to \$54.9 million in the first quarter of 2023, primarily attributable to decreased end-market demand and de-stocking trends across both segments.

Gross profit from continuing operations improved to \$2.5 million, or 5.7% of net sales, compared to \$1.5 million, or 2.7% of net sales, in the first quarter of 2023. The increase was primarily attributable to improved strategic sourcing initiatives and cost improvements.

Net loss from continuing operations decreased to \$4.7 million, or \$(0.47) diluted loss per share, compared to net loss from continuing operations of \$5.8 million, or \$(0.57) diluted earnings per share, in the first quarter of 2023. The decrease was primarily attributable to the aforementioned increases in gross profit and a year-over-year decrease in interest expense due to lower debt outstanding.

Adjusted EBITDA improved to \$(3.1) million compared to \$(3.7) million in the first quarter of 2023, primarily driven by the aforementioned cost optimization efforts. Adjusted EBITDA margin was (7.1)% compared to (6.8)% in the prior year period, with the decline primarily a result of the aforementioned lower net sales base.

Segment Results

Ascent Chemicals – net sales in the first quarter of 2024 were \$20.3 million compared to \$23.7 million in the first quarter of 2023. Operating loss in the first quarter was \$1.4 million compared to operating income of \$1.4 million in the prior year period. Adjusted EBITDA in the first quarter was \$(0.3) million compared to \$2.5 million in the prior year period. As a percentage of segment net sales, adjusted EBITDA was (1.4)% compared to 10.5% in the first quarter of 2023.

Ascent Tubular – net sales from continuing operations in the first quarter of 2024 were \$23.8 million compared to \$31.1 million in the first quarter of 2023. Operating loss from continuing operations in the first quarter decreased to \$1.5 million compared to operating loss from continuing operations of \$3.3 million in the prior year period. Adjusted EBITDA from continuing operations in the first quarter was \$(0.7) million compared to \$(2.4) million in the prior year period. As a percentage of segment net sales, adjusted EBITDA was (3.0)% compared to (7.7)% in the first quarter of 2023.

Liquidity

As of March 31, 2024, the Company had no debt outstanding under its revolving credit facilities and had \$63.6 million in availability under its revolving credit facility.

For the quarter ended March 31, 2024, the Company repurchased 16,330 shares at an average cost of \$9.97 per share for approximately \$0.2 million.

Conference Call

Ascent will conduct a conference call today at 5:00 p.m. Eastern time to discuss its results for the first guarter ended March 31, 2024.

Ascent management will host the conference call, followed by a question-and-answer period.

Date: Wednesday, May 8, 2024 Time: 5:00 p.m. Eastern time Live Call Registration Link: <u>Here</u> Webcast Registration Link: Here

To access the call by phone, please register via the live call registration link above or here and you will be provided with dial-in instructions and details. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

The conference call will also be broadcast live and available for replay via the webcast registration link above or here. The webcast will be archived for one year in the investor relations section of the Company's website at www.ascentco.com.

About Ascent Industries Co.

Ascent Industries Co. (Nasdaq: ACNT) is a company that engages in a number of diverse business activities including the production of specialty chemicals and industrial tubular products. For more information about Ascent, please visit its website at www.ascentco.com.

Forward-Looking Statements

This press release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. All statements that are not historical facts are forward-looking statements. Forward-looking statements can be identified through the use of words such as "estimate," "project," "intend," "expect," "believe," "should," "anticipate," "hope," "optimistic," "plan," "outlook," "should," "could," "may" and similar expressions. The forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements and to review the risks as set forth in more detail in Ascent Industries Co.'s Securities and Exchange Commission filings, including our Annual Report on Form 10-K, which filings are available from the SEC or on our website. Ascent Industries Co. assumes no obligation to update any forward-looking information included in this release.

Non-GAAP Financial Information

Financial statement information included in this earnings release includes non-GAAP (Generally Accepted Accounting Principles) measures and should be read along with the accompanying tables which provide a reconciliation of non-GAAP measures to GAAP measures.

Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, shelf registration costs, loss on extinguishment of debt, retention costs and restructuring & severance costs from net income.

Management believes that these non-GAAP measures are useful because they are key measures used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions as well as allow readers to compare the financial results between periods. Non-GAAP measures should not be considered as an alternative to any measure of performance or financial condition as promulgated under GAAP, and investors should consider the Company's performance and financial condition as reported under GAAP and all other relevant information when assessing the performance or financial condition of the Company. Non-GAAP measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results or financial condition as reported under GAAP.

Ascent Industries Co.

Condensed Consolidated Balance Sheets

(in thousands, except par value and share data)

	•	naudited) March 31, 2024		ecember 31, 2023
Assets				
Current assets:				
Cash and cash equivalents	\$	1,299	\$	1,851
Accounts receivable, net of allowance for credit losses of \$792 and \$463, respectively		28,160		26,604
Inventories		51,197		52,306
Prepaid expenses and other current assets		4,146		4,879
Assets held for sale		1,792		2,912
Current assets of discontinued operations		46		861
Total current assets	_	86,640		89,413
Property, plant and equipment, net		28,648		29,755
Right-of-use assets, operating leases, net		27,431		27,784
Intangible assets, net		8,129		8,496
Deferred income taxes		7,366		5,808
Deferred charges, net		79		104
Other non-current assets, net		2,678		1,935
Total assets	\$	160,971	\$	163,295
Total assets	=		_	
Liabilities and Shareholders' Equity				
Current liabilities:				
Accounts payable	\$	20,549	\$	16,416
Accrued expenses and other current liabilities		4,824		5,108
Current portion of note payable		88		360
Current portion of operating lease liabilities		1,170		1,140
Current portion of finance lease liabilities		288		292
Current liabilities of discontinued operations		1,376		1,473
Total current liabilities		28,295		24,789
Long-term portion of operating lease liabilities		29,419		29,729
Long-term portion of finance lease liabilities		1,236		1,307
Other long-term liabilities		57		60
Total non-current liabilities		30,712		31,096
Total liabilities	\$	59,007	\$	55,885
Commitments and contingencies				
Shareholders' equity:				
Common stock, par value \$1 per share; 24,000,000 shares authorized; 11,085,103 and 10,124,781 shares issued and outstanding, respectively	\$	11,085	\$	11,085
Capital in excess of par value	Ţ	47,097	7	47,333
Retained earnings		53,024		58,517
		111,206		116,935
Less: cost of common stock in treasury - 960,323 and 990,282 shares, respectively		(9,242)		(9,525)
Total shareholders' equity	<u> </u>	101,964		107,410
Total liabilities and shareholders' equity	\$	160,971	\$	163,295
	=			

Note: The condensed consolidated balance sheets at December 31, 2023 have been derived from the audited consolidated financial statements at that date.

Ascent Industries Co.

Condensed Consolidated Statements of Income (Loss) - Comparative Analysis (Unaudited)

(\$ in thousands, except per share data)

Three Months Ended March 31. 2024 2023 Net sales \$ **Tubular Products** \$ 23,814 31,061 Specialty Chemicals 20,296 23,749 50 All Other 54,860 44,110 Operating (loss) income from continuing operations **Tubular Products** (1,502)(3,293)Specialty Chemicals 1,352 (1,439)All Other (162)(479)Corporate Unallocated corporate expenses (2,150)(3,704)(259)Acquisition costs and other (2,150)(3,963)**Total Corporate** Operating loss (5,253)(6,383)Interest expense 127 1,107 (120)(95)Other, net (5,260)(7,395)Loss from continuing operations before income taxes (1,166)(1,607)Income tax benefit Loss from continuing operations (4,094)(5,788)(1,399)589 (Loss) income from discontinued operations, net of tax \$ (5,493)\$ (5,199)Net loss Net loss per common share from continuing operations Basic \$ (0.41)\$ (0.57)Diluted \$ (0.41)\$ (0.57)Net (loss) income per common share from discontinued operations Basic \$ (0.14)\$ 0.06 Diluted \$ \$ 0.06 (0.14)Net loss per common share \$ \$ Basic (0.54)(0.51)Diluted \$ (0.54)\$ (0.51)Average shares outstanding Basic 10.094 10,148 Diluted 10,094 10,148 Other data: Adjusted EBITDA¹ \$ (3,115)\$ (3,735)

¹ The term Adjusted EBITDA is a non-GAAP financial measure that the Company believes is useful to investors in evaluating its results to determine the value of a company. An item is excluded in the measure if its periodic value is inconsistent and sufficiently material that not identifying the item would render period comparability less meaningful to the reader or if including the item provides a clearer representation of normalized periodic earnings. The Company excludes in Adjusted EBITDA two categories of items: 1) Base EBITDA components, including: interest expense, income taxes, depreciation and amortization, and 2) Material transaction costs including: goodwill impairment, asset impairment, gain on lease modification, stock-based compensation, non-cash lease cost, acquisition costs and other fees, retention costs and restructuring & severance costs from net income. For a reconciliation of this non-GAAP measure to the most comparable GAAP equivalent, refer to the Reconciliation of Net Income (Loss) to Adjusted EBITDA.

Ascent Industries Co.

Consolidated Statements of Cash Flows (Unaudited)

(\$ in thousands)

	Three Months	Ended March 31
	2024	2023
Operating activities		
Net loss	\$ (5,493)	\$ (5,199)
(Loss) income from discontinued operations, net of tax	(1,399)	589
Net loss from continuing operations	(4,094)	(5,788)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation expense	1,522	1,549
Amortization expense	367	376
Amortization of debt issuance costs	25	25
Deferred income taxes	(1,166)	353
Provision for (reduction of) losses on accounts receivable	330	(57)
(Reduction of) provision for losses on inventories	(73)	791
Loss on disposal of property, plant and equipment	_	182
Non-cash lease expense	55	64
Stock-based compensation expense	209	319
Changes in operating assets and liabilities:		
Accounts receivable	(1,885)	(1,072)
Inventories	1,182	9,492
Other assets and liabilities	(73)	297
Accounts payable	4,022	6,827
Accrued expenses	(283)	1,629
Accrued income taxes	78	(2,577)
Net cash provided by operating activities - continuing operations	216	12,410
Net cash provided by operating activities - discontinued operations	47	980
Net cash provided by operating activities	263	13,390
Investing activities		
Purchases of property, plant and equipment	(305)	(586)
Net cash used in investing activities - continuing operations	(305)	(586)
Net cash used in investing activities - discontinued operations	(000)	(238)
	(305)	(824)
Net cash used in investing activities	(303)	(024)
Financing activities	50.050	07.400
Borrowings from long-term debt	50,950	67,488
Payments on long-term debt	(50,950)	(80,384)
Payments on note payable	(271)	(289)
Principal payments on finance lease obligations	(76)	(74)
Repurchase of common stock	(163)	(327)
Net cash used in financing activities	(510)	(13,586)
Decrease in cash and cash equivalents	(552)	(1,020)
Less: Cash and cash equivalents of discontinued operations	_	1
Cash and cash equivalents, beginning of period	1,851	1,440
	\$ 1,299	\$ 421

Ascent Industries Co. Non-GAAP Financial Measures Reconciliation Reconciliation of Net Income (Loss) to Adjusted EBITDA (Unaudited) (\$ in thousands)

Consolidated (4,094) (5,788) Adjustments: Interest expense 127 1.106 Income taxes (1,166) (1,607) Depreciation 1,522 1,549 Amortization 367 376 EBITDA (3,244) (4,364) Acquisition costs and other 12 261 Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 3 — Retentucturing and severance costs — 84 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7.1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjusted EBITDA \$ (1,458) \$ 1,342 Adjusted expense 954 952 Action commental color \$ (1,458) \$ 1,342 Specialty Chemicals 19 12 Net (loss) income \$ (1,458) \$ 1,342 Acquisition expense			Three Months Ended March 31,			
Net loss from continuing operations \$ (4,094) \$ (5,788) Adjustments: Interest expense 1,27 1,106 Income taxes (1,166) (1,807) Depreciation 1,522 1,549 Amortization 367 376 EBITDA (3,244) (4,364) Acquisition costs and other 12 261 Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 3 - Restructuring and severance costs - 84 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7,1)% (6,80% Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjustments: 19 12 Interest expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other - 2 Specialty Chemicals Adjusted EBITDA <th>(\$ in thousands)</th> <th></th> <th>2024</th> <th></th> <th>2023</th>	(\$ in thousands)		2024		2023	
Adjustments: Interest expense 127 1,106 Income taxes (1,166) (1,607) Depreciation 1,522 1,549 Amortization 367 376 EBITDA (3,244) (4,364) Acquisition costs and other 12 261 Acquisition costs and other 12 261 Non-cash lease expense 55 64 Retention expense 3 - Restructuring and severance costs - 8 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7,1)% (6,8)% Specialty Chemicals Not (loss) income \$ (1,458) \$ 1,342 Adjusted EBITDA \$ (1,458) \$ 1,342 Adjusted expense 19 12 Depreciation expense 954 952 Adjusted EBITDA (316) 2,484 Acquisition expense 169 158 EBITDA (316) 2,498 Non-cash lease expense 19	Consolidated					
Interest expense 127 1,106 Income taxes (1,166) (1,607) Depreciation 1,522 1,549 Amortization 367 376 EBITDA (3,244) (4,364) Acquisition costs and other 12 261 Slock-based compensation 59 220 Non-cash lease expense 55 64 Retention expenses 3 — Restructuring and severance costs — 84 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7,1)% (6,83%) Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjustments: Interest expense 954 952 Interest expense 954 952 Amortization expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Specialty Chemicals Adjusted EBITDA \$ (29	Net loss from continuing operations	\$	(4,094)	\$	(5,788)	
Income taxes	Adjustments:					
Depreciation 1,522 1,549 Amortization 367 376 EBITDA (3,244) (4,364) Acquisition costs and other 12 261 Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 3 Restructuring and severance costs 84 Adjusted EBITDA \$ (3,115) \$ (3,735) Vs sales (7,1)% (6,8)% Specialty Chemicals \$ (1,458) \$ 1,342 Net (loss) income \$ (1,458) \$ 1,342 Adjustments: 1 1 Interest expense 9 12 Depreciation expense 954 952 Amortization expense 158 158 EBITDA (316) 2,464 Acquisition costs and other (316) 2,464 Acquisition costs and other 9 2 Specialty Chemicals Adjusted EBITDA (390) \$ 2,498 We segment sales						
Amortization 367 376 EBITDA (3,244) (4,364) Acquisition costs and other 12 261 Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 3 — Restructuring and severance costs — 84 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7,1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjustments: 19 12 Interest expense 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ (3,293) Yet loss from continuing operations \$ (1,502)						
Capacitation costs and other 12 261 Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 33	Depreciation					
Acquisition costs and other 12 261 Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 3 — Restructuring and severance costs — 84 Adjusted EBITDA \$ (3.115) \$ (3.735) % sales (7.1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1.458) \$ 1,342 Adjustments: Interest expense 19 12 Depreciation expense 954 952 Amortization expense 954 952 Amortization expense 169 158 BITIDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 2,488 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 Specialty Chemicals Adjusted EBITDA \$ (1,502) \$ (3,293) Autual Products \$ (1,602) \$ (3,293)	Amortization					
Stock-based compensation 59 220 Non-cash lease expense 55 64 Retention expense 3 — Restructuring and severance costs — 84 Adjusted EBITDA \$ (3.115) \$ (3.735) % sales (7.1)% (6.8)% Specialty Chemicals Specialty Chemicals Specialty Chemicals Specialty Chemicals Met (Joss) income \$ (1,458) \$ 1,342 Adjustments: Interest expense 19 12 Depreciation expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 2,498 Specialty Chemicals Adjusted EBITDA \$ (290) \$ (3,293) Adjustments: * * Depreciation expense 54 575 Amortization expense 544 575	EBITDA					
Non-cash lease expense 55 64 Retention expense 3 — Restructuring and severance costs 5 64 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7.1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjustments: 19 12 Interest expense 954 952 Amortization expense 159 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA (290) \$ 2,498 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 Specialty Chemicals adjusted EBITDA \$ (1,502) \$ (3,293) Adjustments: * (1,502) \$ (3,293) Depreciation expense 54 575 Amortization expense 54 575 Amortization						
Retention expense 3 — Restructuring and severance costs — 84 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7.1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjustments: Interest expense 9 1 Interest expense 954 952 Amortization expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other - 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA (290) 2,498 % segment sales (1,4)% 10.5% Tubular Products (1,502) (3,293) Adjustments: 2 3 4 Depreciation expense 544 575 Amortization expense 544 575 Amortizatio	Stock-based compensation				220	
Restructuring and severance costs — 84 Adjusted EBITDA \$ (3,115) \$ (3,735) % sales (7.1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1,458) \$ 1,342 Adjustments: Interest expense 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA (290) 2,498 % segment sales (1,4)% 10.5% Tubular Products (1,502) (3,293) Tubular Products \$ (1,502) (3,293) Adjustments: Popreciation expense 544 575 Amortization expense 544 575 Amortization expense 544 575 Amortization expense 544 575					64	
Adjusted EBITDA \$ (3.115) \$ (3.735) % sales (7.1)% (6.8)% Specialty Chemicals Net (loss) income \$ (1.458) \$ 1.342 Adjustments: Interest expense 954 952 Amortization expense 954 952 Amortization costs and other - 2 Stock-based compensation 7 8 8 Non-cash lease expense 19 9 24 Sepecialty Chemicals Adjusted EBITDA \$ (290) \$ 2.498 % segment sales (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3.293) Adjustments: Depreciation expense 198 218 EBITDA \$ (1,602) \$ (3.293) Adjustments: Depreciation expense 198 218 EBITDA \$ (1,502) \$ (3.293) Adjustments: Depreciation expense 198 218 EBITDA (760) (2.500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Retention expense		3		_	
Adjusted EBITDA (7.1)% (6.8)% Specialty Chemicals (1,458) 1,342 Net (loss) income (1,458) 1,342 Adjustments: 19 12 Interest expense 19 12 Depreciation expense 169 158 EBITDA (316) 2,464 Acquisition costs and other - 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA (290) 2,498 Segment sales (1,4)% 10.5% Tubular Products (1,502) 3,323 Net loss from continuing operations (1,502) 3,323 Adjustments: 2 3,293 Depreciation expense 544 575 Amortization expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 - Stock-based compensation <td>Restructuring and severance costs</td> <td></td> <td></td> <td></td> <td>84</td>	Restructuring and severance costs				84	
Specialty Chemicals Net (loss) income \$ (1,458) 1,342 Adjustments: Interest expense 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 Segment sales (1,4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 <	Adjusted EBITDA	\$	(3,115)	\$	(3,735)	
Net (loss) income \$ (1,458) \$ 1,342 Adjustments: Interest expense 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ (3,293) ** Segment sales (1,4)% 10.5% ** Tubular Products * (1,502) \$ (3,293) ** Adjustments: * (1,502) \$ (3,293) *	% sales		(7.1)%		(6.8)%	
Net (loss) income \$ (1,458) \$ 1,342 Adjustments: Interest expense 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ (3,293) ** Segment sales (1,4)% 10.5% ** Tubular Products * (1,502) \$ (3,293) ** Adjustments: * (1,502) \$ (3,293) *						
Adjustments: 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 % segment sales (1.4)% 10.5% Tubular Products * (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)		_				
Interest expense 19 12 Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 % segment sales (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA (712) \$ (2,405) <		\$	(1,458)	\$	1,342	
Depreciation expense 954 952 Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 Specialty Chemicals Adjusted EBITDA \$ (1,502) \$ (3,293) We loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs # (712) \$ (2,405)						
Amortization expense 169 158 EBITDA (316) 2,464 Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 % segment sales (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	·					
Seliton Seli	Depreciation expense					
Acquisition costs and other — 2 Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 Specialty Chemicals Adjusted EBITDA \$ (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)						
Stock-based compensation 7 8 Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 % segment sales (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)			(316)			
Non-cash lease expense 19 24 Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 % segment sales (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: 2 344 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)			_			
Specialty Chemicals Adjusted EBITDA \$ (290) \$ 2,498 % segment sales (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Stock-based compensation		-			
Specialty Chemicals Adjusted EBITDA (1.4)% 10.5% Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Non-cash lease expense					
Tubular Products Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Specialty Chemicals Adjusted EBITDA	\$ 	(290)	\$	2,498	
Net loss from continuing operations \$ (1,502) \$ (3,293) Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 - Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs - 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	% segment sales		(1.4)%		10.5%	
Adjustments: Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Tubular Products					
Depreciation expense 544 575 Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Net loss from continuing operations	\$	(1,502)	\$	(3,293)	
Amortization expense 198 218 EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Adjustments:					
Tubular Products Adjusted EBITDA (760) (2,500) (2,500)	Depreciation expense		544		575	
EBITDA (760) (2,500) Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Amortization expense		198		218	
Acquisition costs and other 12 — Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	EBITDA		(760)		(2,500)	
Stock-based compensation 11 (20) Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)	Acquisition costs and other					
Non-cash lease expense 25 31 Restructuring and severance costs — 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)					(20)	
Restructuring and severance costs - 84 Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)						
Tubular Products Adjusted EBITDA \$ (712) \$ (2,405)			_		84	
	Tubular Products Adjusted EBITDA	\$	(712)	\$	(2,405)	
	· ·		(3.0)%	-	(7.7)%	

View source version on businesswire.com:

https://www.businesswire.com/news/home/20240508735760/en/

Company Contact

Ryan Kavalauskas Chief Financial Officer 1-630-884-9181

Investor Relations

Cody Slach and Cody Cree Gateway Group, Inc. 1-949-574-3860 ACNT@gateway-grp.com

Source: Ascent Industries Co.